Gut Microbiota: A New Marker of Cardiovascular Disease

Title:Gut Microbiota: A New Marker of Cardiovascular Disease

Volume: 23 Issue: 22

Author(s): Antonio Garcia-Rios, Jose David Torres-Peña, Francisco Perez-Jimenez and Pablo Perez-Martinez*

Affiliation:

• Reina Sofia University Hospital, Lipids and Atherosclerosis Research Unit. Avda. Menéndez Pidal, s/n. 14004 Córdoba,Spain

Keywords: Microbiota, obesity, diabetes, hypertension, lipid metabolism, cardiovascular disease.

Abstract: Cardiovascular disease (CVD) continues to be the major cause of death in the developed countries. Moreover, the cardiovascular risk factors leading towards the development of CVD, mainly type 2 diabetes and obesity, are on the rise. The current preventive and therapeutic management, centred on the control of traditional risk factors, is clearly not enough to stop this pandemic. Therefore, the search for new biomarkers in CVD is a priority in most clinical research programs. Currently, interest in gut microbiota has peaked due to its association with cardiovascular and non-cardiovascular diseases. The present review considers the current situation regarding the influence of gut microbiota on CVD and particularly, its influence on the main traditional risk factors that lead to CVD, such as lipids, diabetes, hypertension and obesity.

Cite this article as:

Garcia-Rios Antonio , Torres-Peña David Jose , Perez-Jimenez Francisco and Perez-Martinez Pablo *, Gut Microbiota: A New Marker of Cardiovascular Disease, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170317144853